SAB Biotherapeutics SABS
NASDAQ SABS
$3.06 -0.11 (-3.47%)
At close: Oct 1, 2026 · 4:00 PM EDT

SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2023)

Updated

SAB Biotherapeutics (SABS) recorded Accumulated Expenses of $1.1 million in Q3 2023, unchanged from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2023) Analysis & Trends

At the end of FY2020, SAB Biotherapeutics reported Accumulated Expenses of $156,201.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 SAB Biotherapeutics 264.67 Mn 264.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 1.10 Mn
Jun 30, 2023 1.10 Mn
Sep 30, 2021 322,376.00
Jun 30, 2021 152,879.00
Mar 31, 2021 80,000.00
Dec 31, 2020 156,201.00
API Access

SAB Biotherapeutics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=SABS&period=max&api_key=YOUR_API_KEY